Skip to main content
. 2021 Jul 19;12(1):274–290. doi: 10.1016/j.apsb.2021.07.009

Figure 4.

Figure 4

In vitro inhibitory activity of compound 36l against two clinical pancreatic cancer cell lines. The primary cell lines 098 and 099 (KRASG12D mutation) were treated with 36l at various concentrations for 72 h. The percentages of viability were measured by CCK8 method. The studies with primary cell lines were approved by the Changhai Hospital Ethics Committee. Data were represented as means ± SEM, n = 3.